⌕
Travere Therapeutics · TVTX · Nasdaq
Tenet 43 · Weak
Compare
$51.10+2.82%At closeTenet 43 · Weak
$51.10+1.40 (+2.82%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Travere Therapeutics (TVTX) Institutional Ownership

13F filers reported holding 24.4% of Travere Therapeutics (TVTX) shares as of Sep 30, 2026, across 158 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
24.4%
Sep 30, 2026
13F filers
158
quarter ended Sep 30, 2026
13F value
$1.4B
23.5M shares
Quarter's fund flow
Mild accumulation
33 new · 15 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (33 new · 67 increased · 40 reduced · 15 closed · 3 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 158 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 49 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Oct 15, 2026Dube Eric MCHIEF EXECUTIVE OFFICERAcquired · Option exercise43,735$26.88↗
Oct 15, 2026Dube Eric MCHIEF EXECUTIVE OFFICERAcquired · Option exercise200,000$8.93↗
Oct 15, 2026Dube Eric MCHIEF EXECUTIVE OFFICERDisposed · Open-market sale128,065$52.97↗
Oct 15, 2026Dube Eric MCHIEF EXECUTIVE OFFICERDisposed · Open-market sale37,270$54.20↗
Oct 15, 2026Dube Eric MCHIEF EXECUTIVE OFFICERDisposed · Open-market sale78,400$55.02↗
Oct 15, 2026Dube Eric MCHIEF EXECUTIVE OFFICERDisposed · Option exercise43,735Employee stock option (right to buy)—↗
Oct 15, 2026Dube Eric MCHIEF EXECUTIVE OFFICERDisposed · Option exercise200,000Employee stock option (right to buy)—↗
Sep 17, 2026Heerma PeterEVP, CHIEF COMMERCIAL OFFICERAcquired · Option exercise8,282$22.40↗
Sep 17, 2026Heerma PeterEVP, CHIEF COMMERCIAL OFFICERDisposed · Open-market sale8,282$65.07↗
Sep 17, 2026Heerma PeterEVP, CHIEF COMMERCIAL OFFICERDisposed · Option exercise8,282Employee stock option (right to buy)—↗
Sep 17, 2026Dube Eric MCHIEF EXECUTIVE OFFICERAcquired · Option exercise108,493$23.34↗
Sep 17, 2026Dube Eric MCHIEF EXECUTIVE OFFICERDisposed · Open-market sale101,691$64.59↗
Sep 17, 2026Dube Eric MCHIEF EXECUTIVE OFFICERDisposed · Open-market sale6,802$64.95↗
Sep 17, 2026Dube Eric MCHIEF EXECUTIVE OFFICERDisposed · Option exercise108,493Employee stock option (right to buy)—↗
Sep 16, 2026Heerma PeterEVP, CHIEF COMMERCIAL OFFICERAcquired · Option exercise100,000$11.25↗
Sep 16, 2026Heerma PeterEVP, CHIEF COMMERCIAL OFFICERAcquired · Option exercise55,000$15.46↗
Sep 16, 2026Heerma PeterEVP, CHIEF COMMERCIAL OFFICERAcquired · Option exercise17,717$26.88↗
Sep 16, 2026Heerma PeterEVP, CHIEF COMMERCIAL OFFICERDisposed · Open-market sale93,604$63.25↗
Sep 16, 2026Heerma PeterEVP, CHIEF COMMERCIAL OFFICERDisposed · Open-market sale79,113$63.65↗
Sep 16, 2026Heerma PeterEVP, CHIEF COMMERCIAL OFFICERDisposed · Option exercise100,000Employee stock option (right to buy)—↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of Travere Therapeutics do institutions hold?

13F filers reported holding 24.4% of Travere Therapeutics' shares as of Sep 30, 2026, across 158 filers.

How many 13F filers hold Travere Therapeutics?

Travere Therapeutics was held by 158 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.